title: Effects of short-course zidovudine on the selection of nevirapine-resistant HIV-1 in women taking single-dose nevirapine.
abstract: Single-dose nevirapine (sdNVP) given to prevent mother-to-child-transmission of HIV-1 selects NVP-resistance. Short-course zidovudine (ZDV) was hypothesized to lower rates of NVP-resistance. HIV-1 infected pregnant women administered sdNVP with or without short-course ZDV were assessed for HIV-1 mutations (K103N, Y181C, G190A, and V106M) prior to delivery and postpartum. Postpartum NVP-resistance was lower among 31 taking ZDV+sdNVP compared to 33 taking only sdNVP (35.5% vs. 72.7%; χ2 P = .003). NVP mutants decayed to <2% in 24/35 (68.6%) at a median 6 months postpartum, with no differences based on ZDV use (logrank P = .99). Short-course ZDV was associated with reduced NVP-resistance mutations among women taking sdNVP.
authors.affiliation: University of Washington, Seattle, Washington,  USA.
authors.forename: Mark A
authors.initials: MA
authors.lastname: Micek
authors.forename: Ana Judith
authors.initials: AJ
authors.lastname: Blanco
authors.forename: Jacquelyn
authors.initials: J
authors.lastname: Carlsson
authors.forename: Ingrid A
authors.initials: IA
authors.lastname: Beck
authors.forename: Sandra
authors.initials: S
authors.lastname: Dross
authors.forename: Laurinda
authors.initials: L
authors.lastname: Matunha
authors.forename: Kristy
authors.initials: K
authors.lastname: Seidel
authors.forename: Pablo
authors.initials: P
authors.lastname: Montoya
authors.forename: Soren
authors.initials: S
authors.lastname: Gantt
authors.forename: Eduardo
authors.initials: E
authors.lastname: Matediana
authors.forename: Lilia
authors.initials: L
authors.lastname: Jamisse
authors.forename: Stephen
authors.initials: S
authors.lastname: Gloyd
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Frenkel
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000494:pharmacology*; D015331:Cohort Studies; D024882:Drug Resistance, Viral; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D006801:Humans; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control; D020125:Mutation, Missense; D019829:Nevirapine / Q000008:administration & dosage / Q000494:pharmacology*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy; D011446:Prospective Studies; D014764:Viral Proteins / Q000235:genetics; D055815:Young Adult; D015215:Zidovudine / Q000008:administration & dosage*
chemical_list: D019380:Anti-HIV Agents; D014764:Viral Proteins; D015215:Zidovudine; D019829:Nevirapine